Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 37

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
 Other non-operating income/(expense) 
     (412) 
     143  
     -  
     (269)
  
    Net loss before income taxes 
    $(10,683) 
    $(3,346) 
    $-  
    $(14,029)
  
    Operating activities included in net loss: 

    Depreciation and amortization 
    $813  
    $20  
    $-  
    $833 
  
    Stock-based compensation expense 
    $1,791  
    $1,338  
    $-  
    $3,129 

    Cash used in operations 
    $(10,982) 
    $(2,367) 
    $-  
    $(13,349)
  
    Cash used in investing 
     8,910  
     7,236  
     -  
     16,146 
  
    Cash from financing 
     21,624  
     -  
     -  
     21,624 
  
    Impact of exchange rates 
     (63) 
     (71) 
     -  
     134 
  
    Net change for the period 
    $19,489  
    $4,798  
    $-  
    $24,287 

    22

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
11 SEGMENTS (continued)

The
following table summarizes financial performance by business segment for the six months ended September 30, 2024:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    NeuroNos  
    Total 
  
    Capital expenditures 
    $3,823  
    $25  
    $          -  
    $3,848 

    Revenues 
    $1,481  
    $-  
    $-  
    $1,481 
  
    Cost of revenues 
     (2,897) 
     -  
     -  
     (2,897)
  
    Research and development 
     (7,510) 
     (3,084) 
     -  
     (10,594)
  
    Selling, general